Cardiology Pharmacy Specialty Literature Study: Module 1A-B (Cert # L199215)

ACPE Numbers: Various – see listing below
Release Date: 4/24/2019
Expiration Dates: 10/22/2019
Activity Type: Application-based
CE Credits: 8 hours

Accreditation for Pharmacists

 The American Society of Health-System Pharmacists and American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Target Audience

The Cardiology Pharmacy Specialty Literature Study is designed to help board-certified pharmacy practitioners who are seeking recertification credit hours to maintain their Board of Pharmacy Specialties (BPS) Board Certification.

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice. 

Module 1A – Antithrombotics/Antiplatelets: This module focuses on antithrombotic therapy in patients with heart failure and atrial fibrallation, as well as antiplatelet therapy in patients with diabetes mellitus. 

Module 1B – Critical Care Cardiology and Endocarditis: This module focuses on the use of epinephrine in cardiac arrest and cardiogenic shock, as well as the partial use of oral antibiotic therapy in endocarditis. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ASHP and ACCP professional development program for BCCP recertification approved by the BPS. 

Recertification Credit*

Board certified pharmacists are eligible to receive up to 8 hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Credit Hours

*Assessment Pass Point

Cardiology Pharmacy Litrature Study Module 1A: Antithrombotics/Antiplatelets

0204-9999-19-953-H01-P

4

75%

Cardiology Pharmacy Litrature Study Module 1B: Critical Care Cardiology and Endocarditis 0204-9999-19-954-H01-P 4

80%

 

Articles and Learning Objectives 

Module 1A - Antithrombotics/Antiplatelets
0204-9999-19-953-H01-P

This module focuses on antithrombotic therapy in patients with heart failure and atrial fibrallation, as well as antiplatelet therapy in patients with diabetes mellitus. 

Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.  N Engl J Med 2018; 379:1332-1342. DOI: 10.1056/NEJMoa1808848.  

Learning Objectives:

  • Explain the rationale, methodology, findings, limitations, and implications of the COMMANDER HF study of rivaroxaban use in patients with recent worsening of chronic heart failure, reduced left ventricular ejection fraction, sinus rhythm, and coronary artery disease without atrial fibrillation
  • Formulate recommendations for the use of rivaroxaban in patients with recent worsening of chronic heart failure and reduced ejection fraction due to ischemic heart disease without atrial fibrillation. 

Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention.  Circulation. 2018;138:527–536. DOI: 10.1161/CIRCULATIONAHA.118.034722. 

Learning Objectives:

  • Explain the changes since 2016 in the 2018 updated focused expert consensus recommendations for antithrombotic therapy in patients with atrial fibrillation (AF) treated with oral anticoagulation (OAC) who have undergone percutaneous coronary intervention (PCI) and stent placement
  • Formulate recommendations for the use of antithrombotic therapy in patients with atrial fibrillation (AF) treated with oral anticoagulation (OAC) who have undergone percutaneous coronary intervention (PCI) and stent placement 

ASCEND Study Collaborative Group, Bowman L, Mafham M et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018; 379:1529-39. 

Learning Objectives:

  • Explain the rationale, methodology, findings, limitations, and implications of A Study of Cardiovascular Events in Diabetes (ASCEND), which assessed the efficacy and safety of aspirin for primary prevention of cardiovascular events in patients with diabetes mellitus
  • Formulate recommendations for primary prevention of cardiovascular events in patients with diabetes mellitus 

Module 1B – Critical Care Cardiology and Endocarditis
0204-9999-19-954-H01-P 

Critical Care Cardiology and Endocarditis: This module focuses on the use of epinephrine in cardiac arrest and cardiogenic shock, as well as the partial use of oral antibiotic therapy in endocarditis. 

Perkins GD, Ji C, Deakin CD et al for the PARAMEDIC2 collaborators. A randomized trial of epinephrine in out-of-hospital cardiac arrest. N Engl J Med. 2018; 379:711-21.   

Learning Objectives:

  • Explain the rationale, methodology, findings, limitations, and implications of the PARAMEDIC2 study of epinephrine treatment for out-of-hospital cardiac arrest
  • Formulate recommendations for the use of epinephrine in adults with out-of-hospital cardiac arrest 

Levy B, Clere-Jehl R, Legras A et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2018; 72:173-82. 

Learning Objectives:

  • Explain the rationale, methodology, findings, limitations, and implications of the OptimaCC study comparing the efficacy and tolerability of epinephrine with norepinephrine in adults with cardiogenic shock after acute myocardial infarction and successful revascularization through percutaneous coronary intervention
  • Formulate recommendations for the use of vasopressors in adults with cardiogenic shock after acute myocardial infarction 

Iversen K, Ihlemann N, Gill SU et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2018(5):415-24.  

Learning Objectives:

  • Explain the rationale, methodology, findings, limitations, and implications of the Partial Oral Treatment of Endocarditis (POET) study
  • Formulate recommendations for the route of administration of antibiotic therapy for adults with left-sided infective endocarditis 

Faculty

Steven Dunn, Pharm.D., BCPS-AQ Cardiology, FAHA, FCCP*
Pharmacy Clinical Coordinator, Heart & Vascular
University of Virginia Health System
Charlottesville, VA 

Genevieve M. Hale, Pharm.D., BCPS
Assistant Professor
Nova Southeastern University College of Pharmacy
Palm Beach Gardens, FL 

Tracy Macaulay, Pharm.D., BCCP, BCPS - AQ Cardiology, AACC*
Cardiology Clinical Specialist
UK HealthCare and Gill Heart Institute
Lexington, NY 

Zachary R. Noel, Pharm.D., BCCP, BCPS
Assistant Professor
University of Maryland School of Pharmacy
Baltimore, MD 

Brent Reed, Pharm.D., BCPS-AQ Cardiology, FAHA*
Associate Professor, Pharmacy Practice and Science
University of Maryland School of Pharmacy
Baltimore, MD 

* Content Matter Experts 

Reviewers

Holly Byrnes, Pharm.D., BCPS, ASHP
Susan R. Dombrowski, B.S. Pharm., M.S. 

Field Testers

Maryam Alikhil, Pharm.D., BCPS, BCCP
Shawn Anderson, Pharm.D., BCACP, BCCP
Anastasia Armbruster, Pharm.D., AACC, BCCP
Katherine Aymond, Pharm.D., BCPS, BCCP
Amy Brewster, Pharm.D, BCPS, BCC
Jessica Casey, Pharm.D., BCPS, BCCP
Julie Cooper, Pharm.D., BCPS-AQ Cardiology, BCCP
Jackoline Costantino, Pharm.D., BCCP
Amr Fahmi, MSc., BCCP
Katelyn Galli, Pharm.D., BCPS, BCCP
Margaret Lassiter, Pharm.D., BCPS-AQ Cardiology, BCCCP, BCCP
Michelle Lew, Pharm.D., BCCP, BCPS
Colleen Linsenmayer, Pharm.D., BCPS, BCCP
Melanie Madorsky, Pharm.D., BCPS, BCCP
Lisa Rhyne, Pharm.D., BCCP
Ryan Servais, Pharm.D., BCPS, BCCCP, BCCP
Pamela Simone, Pharm.D., BCCP, BCPS
Rebecca Tran, Pharm.D., BCPS-AQ Cardiology, BCACP, BCCP, CLS
Kathryn Weber, Pharm.D., BCPS, BCCP
Caitlin Wessels, Pharm.D., BCPS, BCCP
Emily Young, Pharm.D., BCPS, BCCP
Joseph Zieminski, Pharm.D., BCCP 

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and ACCP require that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP, and are required to disclose any relevant financial relationships with commercial interests. ASHP and ACCP identify and resolve conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • All planners, presenters, and reviewers of this session report no financial relationships relevant to this activity. 

Methods and CE Requirements

Activity consists of audio/ video/PDF files, an attestation statement, assessment, and activity evaluation. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessment
  • Complete the evaluation
  • Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

Note: Learner must complete and pass the assessment in order to claim continuing pharmacy education credit. 

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ASHP and ACCP.